Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003014 | 0.81 | CNR2 (0.62) | CNR2LMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14003100 | 0.79 | LMNA (0.35) | CNR2LMNAHPGDALDH1A1NPC1 | |
| SCHEMBL13871399 | 0.79 | CNR2 (0.46) | CNR2LMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL2713702 | 0.76 | CNR2 (0.47) | CNR2ALDH1A1SMN1; SMN2NPC1EPHX2 | |
| SCHEMBL5806477 | 0.76 | CNR2 (0.48) | CNR2LMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5812049 | 0.69 | CNR1 (0.69) | CNR2LMNAHPGDALDH1A1HSD11B1 | |
| SCHEMBL13871341 | 0.69 | CNR2 (0.43) | CNR2LMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13871390 | 0.69 | CNR2 (0.49) | CNR2LMNAHPGDALDH1A1CNR1 | |
| SCHEMBL14003157 | 0.69 | CNR2 (0.47) | CNR2LMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13871722 | 0.68 | CNR2 (0.47) | CNR2LMNAHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | CNR2 1/4885LMNA 4334/4885HPGD 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.